We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Bio-Innovation Agreement to Strengthen Ties between Canada and Israel

By LabMedica International staff writers
Posted on 31 May 2016
A recently signed agreement aims at encouraging academic and entrepreneurial ties in the field of bio-innovation between a Canadian and an Israeli university.

The agreement will establish a strong relationship between the University of Toronto (Canada) – in the form of the Institute of Biomaterials and Biomedical Engineering – and The Hebrew University of Jerusalem (Israel) – in the form of the Alexander Grass Center for Bioengineering.

The agreement, which is called the Jerusalem-Toronto Bio-Innovation Partnership, will strengthen the exchange of students, faculty, and ideas between the academic and entrepreneurial environments of the two universities. More...
In addition, it will provide financial support for students in engineering, biology, and computer science to conduct research in the partner country over a 12-week period.

An intensive eight-week educational program – the Transdisciplinary Innovation Program – that weaves together computer vision, big data, and bioengineering will also be offered to students from the University of Toronto, enabling interaction with Nobel laureates, work under the mentorship of Israeli scientists and entrepreneurs, and the opportunity for students to pitch ideas to investors.

Faculty and student groups will travel between the two countries to advance the collaboration, and a joint BioDesign program will bring together engineers, clinicians, and business and engineering students to share and create knowledge with tangible impact.

Dr. Meric Gertler, president of the University of Toronto, said, “The forthcoming projects with The Hebrew University of Jerusalem are important to the University of Toronto. They underscore a commitment on the part of both universities to harness the power of Israel’s and Canada’s brightest minds to find solutions to the world's pressing social and medical problems. They will provide exciting opportunities in the near-term and, I believe, stand to have meaningful long-run impact by virtue of the skills investment and advances they entail.”

Dr. Menahem Ben-Sasson, president of The Hebrew University of Jerusalem, said, “The Hebrew University is very pleased to expand its partnership with the University of Toronto. This agreement will bring about new exchanges of people and ideas between two of the world’s leading centers of research and academia. Furthermore it will drive cooperation in medical, social and entrepreneurial studies and research that will benefit Canada, Israel and the entire world.”

Related Links:
University of Toronto
The Hebrew University of Jerusalem


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Pipette Calibration System
Artel PCS®
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.